KRAS and colorectal carcinoma: The effectiveness of the FABP4 inhibitor (BMS309403) in the cetuximab-resistant CRC cells harbouring KRAS mutations was evaluated in a xenograft mouse model, where tumors were generated after implantation of patient-derived organoids DTP harboring KRAS mutations (Fig. 7A).